Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to $98.8 million.

  • ARS Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1.83% to $98.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.8 million, marking a year-over-year increase of 1.83%. This contributed to the annual value of $102.4 million for FY2024, which is 7.54% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Shares Outstanding (Diluted Average) is $98.8 million, which was up 0.45% from $98.4 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $102.4 million during Q4 2024, and registered a low of $28.9 million during Q4 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $97.1 million, with a median of $96.8 million in 2024.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Shares Outstanding (Diluted Average) fell by 12.13% in 2022, and later skyrocketed by 210.77% in 2023.
  • ARS Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $28.9 million in 2021, then skyrocketed by 38.39% to $40.0 million in 2022, then soared by 138.30% to $95.2 million in 2023, then rose by 7.54% to $102.4 million in 2024, then increased by 1.83% to $98.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $98.8 million for Q3 2025, versus $98.4 million for Q2 2025 and $98.1 million for Q1 2025.